H. Wedemeyer Et Al. , "PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY," EASL 49 th Annual Meeting of Internation Liver Congress , 2014
Wedemeyer, H. Et Al. 2014. PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY. EASL 49 th Annual Meeting of Internation Liver Congress .
Wedemeyer, H., YURTAYDIN, S. C., Ernst, S., Caruntu, F. A., Curescu, M. G., YALÇIN, K., ... AKARCA, U. S.(2014). PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY . EASL 49 th Annual Meeting of Internation Liver Congress
Wedemeyer, ONUR Et Al. "PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY," EASL 49 th Annual Meeting of Internation Liver Congress, 2014
Wedemeyer, ONUR Et Al. "PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY." EASL 49 th Annual Meeting of Internation Liver Congress , 2014
Wedemeyer, H. Et Al. (2014) . "PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY." EASL 49 th Annual Meeting of Internation Liver Congress .
@conferencepaper{conferencepaper, author={ONUR KESKİN Et Al. }, title={PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY}, congress name={EASL 49 th Annual Meeting of Internation Liver Congress}, city={}, country={}, year={2014}}